Breaking News

Yesterday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
MRTX Mirati Therapeutics $40.04 -1.82 (-4.35%) 13:45 10/21/18 10/21 13:45 10/21/18 13:45 Hot Stocks	Mirati announces updated data from ongoing trial of single agent sitravatinib » Mirati Therapeutics… Mirati Therapeutics announced the completed stage 1 safety and efficacy data from the ongoing Phase 1b clinical trial of single agent sitravatinib in patients with certain classes of oncogenic mutations. The data for a cohort of patients harboring CBL mutations were presented in a proffered poster session at the European Society for Medical Oncology 2018 Congress in Munich, Germany. The presentation provided an update from the pre-planned expansion cohort of the Phase 1b clinical trial of single agent sitravatinib in patients with CBL inactivating mutations. Eight patients were evaluable as of the data cut-off on August 27, 2018. In the subset of evaluable NSCLC patients, 1/2 confirmed partial responses were observed with 2/2 patients experiencing tumor regression. In the subset of evaluable melanoma patients, 1/2 confirmed partial responses in evaluable patients were observed with 1/2 patients experiencing tumor regression. In the subset of evaluable patients with other solid tumors, 2/4 had stable disease with 2/4 experiencing tumor regression. CBL mutations are present in 1.5% of NSCLC, 3.5% of melanoma, and 2% of cancers of unknown origin. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	21 Oct 22 Oct
ABBV AbbVie $88.01 -1.93 (-2.15%) , DCPH Deciphera $22.22 -4.97 (-18.28%) … 04:55 10/21/18 10/21 04:55 10/21/18 04:55 Conference/Events	European Society for Medical Oncology (ESMO) to hold a conference » ESMO 2018 Congress to be… ESMO 2018 Congress to be held in Munich, Germany on October 19-23. ABBV AbbVie $88.01 -1.93 (-2.15%) DCPH Deciphera $22.22 -4.97 (-18.28%) TSRO Tesaro $41.81 -1.19 (-2.77%) IMGN ImmunoGen $7.44 -0.355 (-4.56%) REGN Regeneron $389.94 -5.45 (-1.38%) CRSP Crispr Therapeutics $36.02 -1.18 (-3.17%) CLVS Clovis $26.41 -3.54 (-11.82%) MRTX Mirati Therapeutics $40.04 -1.82 (-4.35%) LOXO Loxo Oncology $160.01 -7.58 (-4.52%) RHHBY Roche $0.00 (0.00%) NCNA NuCana $18.90 1.9 (11.18%) CRVS Corvus Pharmaceuticals $8.01 -0.1 (-1.23%) NTGN Neon Therapeutics $8.88 0.56 (6.73%) NKTR Nektar $48.23 -1.33 (-2.68%) EXEL Exelixis $16.27 -0.25 (-1.51%) AVEO Aveo Pharmaceuticals $2.50 -0.03 (-1.19%) KURA Kura Oncology $14.38 -1.18 (-7.58%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	21 Oct 22 Oct 22 Oct 24 Oct 28 Oct 30 Oct 01 Nov 01 Nov 02 Nov 02 Nov 06 Nov 07 Nov 10 Nov 26 Nov 27 Nov 24 Dec 14 Jan 28 Apr 13 May

Saturday
ABBV AbbVie $88.01 -1.93 (-2.15%) , DCPH Deciphera $22.22 -4.97 (-18.28%) … 04:55 10/20/18 10/20 04:55 10/20/18 04:55 Conference/Events	European Society for Medical Oncology (ESMO) to hold a conference » ESMO 2018 Congress to be… ESMO 2018 Congress to be held in Munich, Germany on October 19-23. ABBV AbbVie $88.01 -1.93 (-2.15%) DCPH Deciphera $22.22 -4.97 (-18.28%) TSRO Tesaro $41.81 -1.19 (-2.77%) IMGN ImmunoGen $7.44 -0.355 (-4.56%) REGN Regeneron $389.94 -5.45 (-1.38%) CRSP Crispr Therapeutics $36.02 -1.18 (-3.17%) CLVS Clovis $26.41 -3.54 (-11.82%) MRTX Mirati Therapeutics $40.04 -1.82 (-4.35%) LOXO Loxo Oncology $160.01 -7.58 (-4.52%) RHHBY Roche $0.00 (0.00%) NCNA NuCana $18.90 1.9 (11.18%) CRVS Corvus Pharmaceuticals $8.01 -0.1 (-1.23%) NTGN Neon Therapeutics $8.88 0.56 (6.73%) NKTR Nektar $48.23 -1.33 (-2.68%) EXEL Exelixis $16.27 -0.25 (-1.51%) AVEO Aveo Pharmaceuticals $2.50 -0.03 (-1.19%) KURA Kura Oncology $14.38 -1.18 (-7.58%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	20 Oct 20 Oct 22 Oct 22 Oct 24 Oct 28 Oct 30 Oct 01 Nov 01 Nov 02 Nov 02 Nov 06 Nov 07 Nov 10 Nov 26 Nov 27 Nov 24 Dec 14 Jan 28 Apr 13 May

Friday
MRTX Mirati Therapeutics $40.04 -1.82 (-4.35%) 16:53 10/19/18 10/19 16:53 10/19/18 16:53 Conference/Events	Mirati Therapeutics to hold a conference call » Dr. Charles Baum… Dr. Charles Baum discusses the updated Sitravatinib clinical data presented at the 2018 ESMO Annual Meeting on a conference call to be held on October 22 at 8 am. Webcast Link 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	19 Oct
ABBV AbbVie $89.94 -2.27 (-2.46%) , DCPH Deciphera $27.19 -1.51 (-5.26%) … 08:11 10/19/18 10/19 08:11 10/19/18 08:11 Conference/Events	European Society for Medical Oncology (ESMO) to hold a conference » ESMO 2018 Congress to be… ESMO 2018 Congress to be held in Munich, Germany on October 19-23. ABBV AbbVie $89.94 -2.27 (-2.46%) DCPH Deciphera $27.19 -1.51 (-5.26%) TSRO Tesaro $43.00 -1.33 (-3.00%) IMGN ImmunoGen $7.79 -0.135 (-1.70%) REGN Regeneron $395.39 -3.29 (-0.83%) CRSP Crispr Therapeutics $37.20 -2.58 (-6.49%) CLVS Clovis $29.95 -1.43 (-4.56%) MRTX Mirati Therapeutics $41.86 -0.3 (-0.71%) LOXO Loxo Oncology $167.59 -0.83 (-0.49%) RHHBY Roche $0.00 (0.00%) NCNA NuCana $17.00 -0.76 (-4.28%) CRVS Corvus Pharmaceuticals $8.11 -0.53 (-6.13%) NTGN Neon Therapeutics $8.32 0.31 (3.87%) NKTR Nektar $49.56 -1.02 (-2.02%) EXEL Exelixis $16.52 -0.5 (-2.94%) AVEO Aveo Pharmaceuticals $2.53 -0.145 (-5.42%) KURA Kura Oncology $15.56 -0.34 (-2.14%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	19 Oct 19 Oct 20 Oct 22 Oct 24 Oct 28 Oct 30 Oct 01 Nov 01 Nov 02 Nov 02 Nov 06 Nov 07 Nov 10 Nov 26 Nov 27 Nov 24 Dec 14 Jan 28 Apr 13 May

Over a week ago
GALT Galectin Therapeutics $5.40 -0.33 (-5.76%) , MRTX Mirati Therapeutics $46.57 -0.92 (-1.94%) … 08:45 10/03/18 10/03 08:45 10/03/18 08:45 Options	Largest borrow rate increases among liquid names » Latest data shows the… Latest data shows the largest indicative borrow rate increases among liquid option names include: Galectin Therapeutics (GALT) 57.15% +2.76, Mirati Therapeutics (MRTX) 1.45% +0.85, Marvell (MRVL) 4.69% +0.47, Camping World (CWH) 7.45% +0.24, Adamis Pharmaceuticals (ADMP) 25.80% +0.22, Direxion Daily Gold Miners Bull 3X Shares (NUGT) 2.80% +0.10, Cronos Group (CRON) 35.12% +0.09, Alerian (AMLP) 1.81% +0.09, Sierra Wireless (SWIR) 2.11% +0.08, and Franco-Nevada (FNV) 0.66% +0.07. GALT Galectin Therapeutics $5.40 -0.33 (-5.76%) MRTX Mirati Therapeutics $46.57 -0.92 (-1.94%) MRVL Marvell $19.41 0.14 (0.73%) CWH Camping World $19.51 -0.49 (-2.45%) ADMP Adamis Pharmaceuticals $3.20 -0.01 (-0.31%) NUGT Direxion Gold Miners Bull $14.03 1.1 (8.51%) CRON Cronos Group $10.71 -0.61 (-5.39%) SWIR Sierra Wireless $19.34 -0.39 (-1.98%) FNV Franco-Nevada $65.38 2.435 (3.87%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	08 Oct 17 Oct 06 Nov 13 Nov 27 Nov
MRTX Mirati Therapeutics $48.93 -1.225 (-2.44%) 15:34 09/27/18 09/27 15:34 09/27/18 15:34 Recommendations	Mirati Therapeutics analyst commentary at Cowen » Mirati Therapeutics… Mirati Therapeutics weakness a buying opportunity, says Cowen. Cowen analyst Chris Sibutani said he sees the pullback in Mirati Therapeutics shares as an attractive buying opportunity and reiterates his Outperform rating on the stock. There was never a reason to expect that Mirati's data was under consideration for a late-breaking abstract presentation at ESMO, Sibutani tells investors. He expects management to share their plans for the sitravatinib + nivolumab pivotal study program at the ESMO meeting after data is presented on Monday, October 22. The analyst maintains an Outperform rating on Mirati shares. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a month ago
MRTX Mirati Therapeutics $54.70 -0.55 (-1.00%) 16:45 09/17/18 09/17 16:45 09/17/18 16:45 Initiation	Mirati Therapeutics initiated at Guggenheim » Mirati Therapeutics… Mirati Therapeutics initiated with a Neutral at Guggenheim. Target $54. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
MRTX Mirati Therapeutics $52.65 -4 (-7.06%) 16:05 09/06/18 09/06 16:05 09/06/18 16:05 Syndicate	Breaking Syndicate news story on Mirati Therapeutics » Mirati Therapeutics files… Mirati Therapeutics files automatic mixed securities shelf 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
ARCT Arcturus Therapeutics $8.10 0.05 (0.62%) , BTX BioTime $2.74 0.04 (1.48%) … 07:22 09/04/18 09/04 07:22 09/04/18 07:22 Conference/Events	B. Riley FBR to hold a conference » Annual B. Riley FBR… Annual B. Riley FBR Healthcare Conference will be held in New York on September 4. ARCT Arcturus Therapeutics $8.10 0.05 (0.62%) BTX BioTime $2.74 0.04 (1.48%) EIGR Eiger BioPharmaceuticals $12.75 0.05 (0.39%) ALNY Alnylam $122.69 0.7 (0.57%) SRNE Sorrento Therapeutics $5.55 0.05 (0.91%) MDCO The Medicines Co. $39.60 -0.66 (-1.64%) SBPH Spring Bank Pharmaceuticals $14.11 -0.63 (-4.27%) GERN Geron $5.73 0.33 (6.11%) IFRX InflaRx $33.59 0.19 (0.57%) IOVA Iovance Biotherapeutics $17.65 (0.00%) CUE Cue Biopharma $9.60 0.55 (6.08%) MGTX MeiraGTx $11.70 0.19 (1.65%) MRTX Mirati Therapeutics $56.55 -0.4 (-0.70%) VSTM Verastem $9.96 (0.00%) TNXP Tonix Pharmaceuticals $1.07 0.055 (5.42%) SRTS Sensus Healthcare $7.17 -0.14 (-1.92%) AVEO Aveo Pharmaceuticals $2.98 0.055 (1.88%) APLS Apellis $19.34 0.2 (1.04%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	04 Sep 04 Sep 05 Sep 06 Sep 07 Sep 07 Sep 11 Sep 12 Sep 13 Sep 05 Oct

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial